139 related articles for article (PubMed ID: 37335173)
21. Changes of IL-6 And IFN-γ before and after the adverse events related to immune checkpoint inhibitors: A retrospective study.
Zhang X; Lu X; Yu Y; Tan K; Cui H
Medicine (Baltimore); 2022 Nov; 101(46):e31761. PubMed ID: 36401365
[TBL] [Abstract][Full Text] [Related]
22. Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines.
Kang JH; Bluestone JA; Young A
Trends Immunol; 2021 Apr; 42(4):293-311. PubMed ID: 33714688
[TBL] [Abstract][Full Text] [Related]
23. A nomogram model for predicting the risk of checkpoint inhibitor-related pneumonitis for patients with advanced non-small-cell lung cancer.
Zhang Y; Zhang L; Cao S; Wang Y; Ling X; Zhou Y; Zhong H
Cancer Med; 2023 Aug; 12(15):15998-16010. PubMed ID: 37409360
[TBL] [Abstract][Full Text] [Related]
24. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
[TBL] [Abstract][Full Text] [Related]
25. Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors.
Bai R; Li L; Chen X; Chen N; Song W; Zhang Y; Lv Z; Han F; Zhao Y; Li W; Cui J
J Oncol; 2021; 2021():9935076. PubMed ID: 34335763
[TBL] [Abstract][Full Text] [Related]
26. Stocking the toolbox-Using preclinical models to understand the development and treatment of immune checkpoint inhibitor-induced immune-related adverse events.
Cina ML; Venegas J; Young A
Immunol Rev; 2023 Sep; 318(1):110-137. PubMed ID: 37565407
[TBL] [Abstract][Full Text] [Related]
27. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
[TBL] [Abstract][Full Text] [Related]
28. [Predictive Biomarkers of Immune-related Adverse Events Induced by Checkpoint Inhibitors in Malignancies].
Tang H; Guan M; Sun Z; Bai CM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Dec; 42(6):825-830. PubMed ID: 33423733
[TBL] [Abstract][Full Text] [Related]
29. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
30. Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Sonehara K; Tateishi K; Araki T; Komatsu M; Akahane J; Yamamoto H; Hanaoka M
Cancer Manag Res; 2022; 14():427-435. PubMed ID: 35140520
[TBL] [Abstract][Full Text] [Related]
31. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Akamatsu H; Murakami E; Oyanagi J; Shibaki R; Kaki T; Takase E; Tanaka M; Harutani Y; Yamagata N; Okuda Y; Furuta K; Sugimoto T; Teraoka S; Hayata A; Tokudome N; Ozawa Y; Mori K; Koh Y; Yamamoto N
Oncologist; 2020 Apr; 25(4):e679-e683. PubMed ID: 32297443
[TBL] [Abstract][Full Text] [Related]
32. Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer.
Berti A; Bortolotti R; Dipasquale M; Kinspergher S; Prokop L; Grandi G; Inchiostro S; Paolazzi G; Caffo O; Veccia A
Crit Rev Oncol Hematol; 2021 Jun; 162():103351. PubMed ID: 33989769
[TBL] [Abstract][Full Text] [Related]
33. Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Suazo-Zepeda E; Bokern M; Vinke PC; Hiltermann TJN; de Bock GH; Sidorenkov G
Cancer Immunol Immunother; 2021 Nov; 70(11):3069-3080. PubMed ID: 34195862
[TBL] [Abstract][Full Text] [Related]
34. Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Petrelli F; Grizzi G; Ghidini M; Ghidini A; Ratti M; Panni S; Cabiddu M; Ghilardi M; Borgonovo K; Parati MC; Tomasello G; Barni S; Berruti A; Brighenti M
J Immunother; 2020 Jan; 43(1):1-7. PubMed ID: 31574022
[TBL] [Abstract][Full Text] [Related]
35. Eosinophil and IFN-γ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy.
Hu WT; Zhang Q; Zhang Z; He X; Zhou M; Guo Y; Wang X
Front Immunol; 2023; 14():1112409. PubMed ID: 36949952
[TBL] [Abstract][Full Text] [Related]
36. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
[TBL] [Abstract][Full Text] [Related]
37. Development and validation of a nomogram for predicting the occurrence of renal dysfunction after treatment of immune checkpoint inhibitor: a retrospective case-control study.
Su J; Chen P; Yang Y; Gao Z; Bi Z; Feng M
BMJ Open; 2024 May; 14(5):e082484. PubMed ID: 38760047
[TBL] [Abstract][Full Text] [Related]
38. Uncovering the flip side of immune checkpoint inhibitors: a comprehensive review of immune-related adverse events and predictive biomarkers.
Miao YD; Quan WX; Tang XL; Shi WW; Li Q; Li RJ; Wang JT; Gan J; Dong X; Hao L; Luan WY; Zhang F
Int J Biol Sci; 2024; 20(2):621-642. PubMed ID: 38169638
[TBL] [Abstract][Full Text] [Related]
39. Immune-related adverse events correlate with the efficacy of PD-1 inhibitors combination therapy in advanced cholangiocarcinoma patients: A retrospective cohort study.
Zhang Y; Wang X; Li Y; Hong Y; Zhao Q; Ye Z
Front Immunol; 2023; 14():1141148. PubMed ID: 37033935
[TBL] [Abstract][Full Text] [Related]
40. Advances on immune-related adverse events associated with immune checkpoint inhibitors.
Fan Y; Geng Y; Shen L; Zhang Z
Front Med; 2021 Feb; 15(1):33-42. PubMed ID: 32779094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
